Citrix Systems Inc
Change company Symbol lookup
Select an option...
CTXS Citrix Systems Inc
RAKR Rainmaker Worldwide Inc
CLB Core Laboratories NV
KERN Akerna Corp
T AT&T Inc
YPPN Yappn Corp
RUSHB Rush Enterprises Inc
CMTL Comtech Telecommunications Corp
BMYMP Bristol-Myers Squibb Co
GOOG Alphabet Inc
Go

Information Technology : Software | Mid Cap Blend
Company profile

Citrix Systems, Inc. offers Enterprise and Service Provider products, which include Workspace Services solutions and Delivery Networking products. The Company's Enterprise and Service Provider products include Cloud Services solutions, and related license updates and maintenance, support and professional services. The Company's NetScaler nCore Technology is an architecture that enables execution of multiple packet engines in parallel. The Company's workspace services include Application Virtualization and virtual desktop infrastructure (VDI), Enterprise Mobility Management and Citrix Workspace Suite. The Company's NetScaler ADC is a software-defined application delivery controller (ADC) and load balancer. The Company's Cloud Services include ShareFile and Citrix Cloud. It provides various ways for customers to receive upgrades, support and maintenance for products, which include Software Maintenance, Subscription Advantage, Technical Support Services and Hardware Maintenance.

Premarket

Last Trade
Delayed
$137.92
1.56 (1.14%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$136.36
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
4,573

10-day average volume:
1,164,498
4,573

UPDATE: Inovio shares tumble 8% after short seller Muddy Waters says don't believe the COVID-19 vaccine hype

2:17 pm ET September 2, 2020 (MarketWatch)
Print

Inovio Pharmaceuticals Inc. shares (INO) slid 8% Wednesday, after Muddy Waters said it has taken a short position in the stock, which has been boosted this year by high hopes for its COVID-19 vaccine candidate. The short selling firm, led by investor Carson Block, said in a series of tweets that a recent court decision (https://drive.google.com/file/d/1K4wnKDH4EkqjYE6QufL1pvlYuwYKEkEU/view) "makes it clear that Inovio lacks manufacturing capacity to get remotely near purported goal of 1 million doses in 2020 and 100 million in 2021." The decision was made in a case Inovio brought against GeneOne Life Science Inc. and VGXI Inc. over a supply agreement. Muddy Waters also noted that Citron Research, another short seller, had compared Inovio to scandal-ridden Theranos earlier this year (https://citronresearch.com/wp-content/uploads/2020/04/Inovio-Pharmaceuticals-Bad-Blood.pdf)and called it 'one of the longest running and most blatant stock promotion schemes ever witnessed." "We concur," said Muddy Waters. Inovio makes DNA based vaccines and immunotherapies for a range of diseases, including HPV and Zika, but hasn't yet had a product approved for treatment. The company is currently conducting a Phase 1 trial of its vaccine candidate, INO-4800, and has said it expects to start Phase 2/3 trials in September. The company did not immediately respond to a request for comment. Shares are still up 218% in the year to date.

-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

September 02, 2020 14:17 ET (18:17 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.